**Tutorial Assignment 3**

Dawn Opert

OPRNET001

PSY3011S: Clinical Psychology II

Katya Kee-Tui

12 October 2022

**Plagiarism Declaration**

1. I know that plagiarism is wrong. Plagiarism means to present substantial portions

or elements of another’s work, ideas or data as my own, even if the original author

is cited occasionally.

2. I have used the American Psychological Association formatting for citation and

referencing. Each significant contribution to, and quotation in, this

essay/project/report from the work or works of other people has been attributed,

cited and referenced.

3. This essay/project/report is my own work.

4. **I have not allowed, and will not allow anyone to copy my work with the**

**intention of passing it off as their own work.**

**Signed:** Dawn Opert

**Date:** 12 October 2022

**Introduction**

Attenuated Psychosis Syndrome (APS) is a construct which attempts to describe an individual who is in the earliest stages of a psychotic disorder, when symptoms have begun to manifest but before they have reached the severity threshold of a full disorder such as Schizophrenia (American Psychiatric Association [APA], 2013; Corcoran et al., 2021; Mahli and Bell, 2019; Zachar et al., 2020). Without delving too deeply into the history, APS was developed in an effort to identify the early signs of psychosis development, and to provide treatment in order to mitigate the harm it causes and inhibit its development (Carpenter, 2020; Corcoran et al., 2021; Mahli and Bell, 2019; Zachar et al., 2020). Originally, this syndrome was added to an index of the DSM-5 which signalled the need for more research. Recently, there have been calls for APS to be moved from this index into the main section of the DSM-5 in the next DSM revision, giving rise to heated debate regarding how wise this decision is (Carpenter, 2020; Corcoran et al., 2021; Mahli and Bell, 2019). As the background has been established, this paper will now outline the argument for the inclusion of APS, the criticism and responses, and then conclude with a possible remedy for the challenges APS faces.

**Support and Criticism for APS**

In the case of a normal psychosis diagnosis, there has usually been an enormous amount of harm to the client by the time the first psychotic episode occurs (Carpenter, 2020; Zachar et al., 2020). The primary benefit of APS is that it facilitates the detection and treatment of developing psychotic symptoms before they get to this point, saving the client from serious complications and improving the chances for better results (Carpenter, 2020; Zachar et al., 2020). Additionally, APS in the main DSM-5 will be a signal for more focused research and clinician education on the period before a full psychotic disorder is clearly recognisable, and a move away from framing psychosis as all-or-nothing and discrete (Carpenter, 2020; Corcoran et al., 2021; Zachar et al., 2020).

However, there have been a number of issues raised with regards to APS. Firstly, the criteria for APS are ambiguous, only requiring the presence of a single symptom for diagnosis and relying on a vaguely defined threshold of a client’s insight into their symptom’s non-reality (Mahli and Bell, 2019). Essentially, there is no way to clearly define the edges of APS, making its use practically difficult (Mahli and Bell, 2019). This compounds a second issue: ambiguity makes misdiagnosis and false-positives more likely, leading to potential sources of stigma (Corcoran et al., 2021; Mahli and Bell, 2019; Zachar et al., 2020). Further some clinicians may treat a diagnosis of APS as a *de facto* diagnosis of Schizophrenia, and treat it as such with inappropriate prescription of anti-psychotic medication, even in cases where clinical guidelines refrain from their use (Carpenter, 2020; Corcoran et al., 2021; Mahli and Bell, 2019; Zachar et al., 2020). Finally, there have been issues raised regarding the reliability of APS as a predictor of Schizophrenia or other psychotic disorder. Specifically, only about a quarter of clients who could be diagnosed with APS go on to develop Schizophrenia, and of this fraction there is a large number who functionally qualify for a full psychotic disorder diagnosis already that is just being held at the levels of attenuated psychotic symptoms by use of anti-psychotic medication already (Mahli and Bell, 2019; Raballo et al., 2020).

Inclusion in the main section of the DSM-5 will open the door to the development of proper training and treatment guidelines (Carpenter, 2020; Corcoran et al., 2021; Zachar et al., 2020). This will in turn reduce the likelihood of misdiagnosis as clinicians are properly trained, and will allow treatment guidelines to solidify and prevent the inappropriate prescription of anti-psychotic medication (Carpenter, 2020; Corcoran et al., 2021; Zachar et al., 2020). Furthermore, stigma seems to be more associated with the symptoms of psychotic disorder than the label of psychotic disorders, so the risk regarding an APS diagnosis should still be lower than with a full psychotic disorder, and in all cases should be managed with education (Carpenter, 2020; Corcoran et al., 2021). Finally, even a 10% of individuals with APS progressing to a full psychotic disorder is still significantly higher than the general population, and further those that do not progress may either be worth studying for what they can tell us about resiliency or otherwise may have been helped by treatment for APS in the first place (Carpenter, 2020; Corcoran et al., 2021). Otherwise, research does suggest that there is a high enough reliability and validity rate to begin locking down a diagnosis definition for APS (Raballo et al., 2020).

**Conclusion**

While there is solid criticism of the move to add APS to the main section of DSM-5, reasonable responses have been offered and recent research has closed many of the gaps that previously existed. As discussed above, there are still challenges that proponents of APS face, but these are not insurmountable. While there are always issues associated with adding a new diagnosis to the DSM, the inclusion of APS seems to be a net positive for the reasons outlined above. Doing so will also put it in a position where the final gaps in the criteria can be closed and research can be converted into practical clinical guidelines.

**References**

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5* (5th ed.).

Carpenter, W. (2020). Classification is essential for the attenuated psychosis syndrome. *Biological Psychiatry, 88*, 289–290. <https://doi.org/10.1016/j.biopsych.2019.08.013>

Corcoran, C., Mittal, V., & Woods, S. (2021). Attenuated psychosis syndrom should be moved to the main section in DSM-5-TR. *JAMA Psychiatry, 78* (8), 821–822. <https://doi.org/10.1001/jamapsychiatry.2021.0838>

Mahli, G., & Bell, E. (2019). Make news: Attenuated psychosis syndrome - a premature speculation? *Australian & New Zealand Journal of Psychiatry, 53* (10), 1028–1032. <https://doi.org/10.1177/0004867419878262>

Raballo, A., Poletti, M., & Preti, A. (2020). Attenuated psychosis syndrome or pharmacologically attenuated first-episode psychosis? an undesirably widespread confounder. J*AMA Psychiatry, 77* (12), 1213–1214. <https://doi.org/10.1001/jamapsychiatry/2020/1634>

Zachar, P., First, M., & Kendler, K. (2020). The DSM-5 proposal for attenuated psychosis syndrome: A history. *Psychological Medicine, 50*, 920–926. <https://doi.org/10.1017/S0033291720000653>